01 / DESIGN
What was studied?
Adults with diabetes inadequately controlled through diet and exercise were randomized to mazdutide or placebo for the controlled phase of a phase 3 trial.
02 / FINDINGS
What did the researchers report?
Glycated hemoglobin and body-weight outcomes favored mazdutide at the controlled endpoint. Diarrhea, nausea and decreased appetite were among the reported adverse events.
03 / LIMITS
How should it be interpreted?
An extension phase followed the placebo-controlled comparison. Controlled and extended observations should not be combined as if they provide the same strength of comparative evidence.
Voltera Peptide editorial reading note. Based on the linked source record. Methods and corrections.